Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLS-0071 Phase 1 in Healthy Volunteers
NCT05298787Phase 1Completed
- Sponsor
- ReAlta Life Sciences
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegtarazimod in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by ReAlta Life Sciences. Primary endpoints: Incidence of adverse events and Incidence of abnormal laboratory test results. Started Jan 2021; status: completed.
02
Drugs
pegtarazimod
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05298787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298787.